Personalized tumor-loaded monocyte-derived dendritic cell vaccination in combination with atezolizumab as maintenance treatment in extensive-stage small cell lung cancer (ES-SCLC): phase Ib-II VENEZOLUNG trial

Maria Gonzalez-Cao, Marta Sisteré-Oró, Teresa Moran, Noemi Reguart, Raquel Cabezon, Andres Aguilar Hernández, Ruth Roman, Miguel A Molina-Vila, Kürşat Birgin, Eva Domenjo-Vila, Gemma Piqué, Miquel Lozano, Paola Charry, Roxana Reyes, Irene Moya, Lluis Cirera, Carlos Esparre, Ana Drozdowskyj, Elizabeth Martínez Pérez, Rafael Rosell, Manel Juan, Andreas Meyerhans, Daniel Benitez-Ribas · 2026

Read Personalized tumor-loaded monocyte-derived dendritic cell vaccination in combination with atezolizumab as maintenance treatment in extensive-stage small cell lung cancer (ES-SCLC): phase Ib-II VENEZOLUNG trial by Maria Gonzalez-Cao, Marta Sisteré-Oró, Teresa Moran, Noemi Reguart, Raquel Cabezon, Andres Aguilar Hernández, Ruth Roman, Miguel A Molina-Vila, Kürşat Birgin, Eva Domenjo-Vila, Gemma Piqué, Miquel Lozano, Paola Charry, Roxana Reyes, Irene Moya, Lluis Cirera, Carlos Esparre, Ana Drozdowskyj, Elizabeth Martínez Pérez, Rafael Rosell, Manel Juan, Andreas Meyerhans, Daniel Benitez-Ribas (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/PMC13410713.txt.

Description

Maria Gonzalez-Cao and colleagues report in 2026 an early trial of a personal vaccine for widespread small cell lung cancer. This fast cancer responds to first treatment, then usually returns. The vaccine uses a patient's own tumor material loaded onto immune starter cells, paired with a checkpoint drug as upkeep therapy.

Twenty patients joined, including six whose cancer had reached the brain. Eighteen received the vaccine, with a median of three doses. Vaccine side effects stayed mild, mostly brief skin irritation at the injection site. Among those assessed, about 94 percent saw tumors respond. Two years on, about a fifth remained free of progression, a figure the team calls promising for such an aggressive disease.

Catalog record

CREATORMaria Gonzalez-Cao, Marta Sisteré-Oró, Teresa Moran, Noemi Reguart, Raquel Cabezon, Andres Aguilar Hernández, Ruth Roman, Miguel A Molina-Vila, Kürşat Birgin, Eva Domenjo-Vila, Gemma Piqué, Miquel Lozano, Paola Charry, Roxana Reyes, Irene Moya, Lluis Cirera, Carlos Esparre, Ana Drozdowskyj, Elizabeth Martínez Pérez, Rafael Rosell, Manel Juan, Andreas Meyerhans, Daniel Benitez-Ribas
YEAR2026
COLLECTIONPAPERS
FORMATTXT
FILE SIZE43 KB
LICENSEhttps://creativecommons.org/licenses/by/4.0
RIGHTSCC BY
SOURCEEurope PMC

Source: https://europepmc.org/article/MED/PMC13410713

Browse the full library · About the Tower of Babel